<DOC>
	<DOC>NCT02856464</DOC>
	<brief_summary>The trial will be conducted as a multicentre open label, randomised prospective phase II clinical trial in patients with high risk myeloid malignancies. The primary objective is to evaluate whether prophylactic donor lymphocyte infusions (DLI) delivered as part of a planned schedule improves the disease free survival of patients with myeloid malignancies.</brief_summary>
	<brief_title>Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>Patient Inclusion Criteria 1. Haematological cancer which can be one of the following 1. Acute Myeloid Leukaemia (AML) if Intermediate or High risk in CR1 2. AML if favourable risk in CR2 3. Patients with AML or MDS with residual cytogenetic or molecular disease preHSCT 4. CMML 5. Myelodysplastic Syndrome (MDS) defined by an IPSS category int1 or higher with &lt;5% blasts at the time of randomisation following cytoreduction if necessary 6. Secondary MDS or AML; defined as arising from antecedent haematological disease or secondary to prior chemotherapy. 2. Patients with sibling or 9/10 or 10/10 HLA matched unrelated donor 3. Patients receiving alemtuzumab based reduced intensity conditioned HSCT 4. Age &gt;/=18 years 5. Able to comprehend and give informed consent Patient Exclusion Criteria 1. Patients with &gt;5% blasts at time of HSCT 2. Patients eligible for myeloablative (Bu/Cy of Cy/TBI) HSCT protocols 3. Patients with myelofibrosis 4. Patients with hypersensitivity to alemtuzumab, melphalan, fludarabine or busulphan 5. ECOG performance status &gt; 2 6. Patients who are pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>